Engineered single-domain antibodies with high protease resistance and thermal stability

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Hussack, Greg ^a,b   Hirama, Tomoko ^a   Ding, Wen ^a   MacKenzie, Roger ^a,c   Tanha, Jamshid ^a,b,c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; CLOSTRIDIUM DIFFICILE TOXIN A; PEPSIN A; PROTEINASE; TOXIN ANTIBODY;

ACIDITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DISULFIDE BOND; HEAVY CHAIN; HYDROPHOBICITY; IN VITRO STUDY; MASS SPECTROMETRY; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN UNFOLDING; THERMAL EXPOSURE; THERMOSTABILITY; ULTRAVIOLET SPECTROSCOPY; WILD TYPE;

AMINO ACID SEQUENCE; ANTIBODIES; BACTERIAL TOXINS; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; DISULFIDES; ENTEROTOXINS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; NEUTRALIZATION TESTS; PEPTIDE HYDROLASES; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN UNFOLDING; TEMPERATURE;

EID: 82355161910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028218     Document Type: Article

References (70)

1. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ, (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6: 17-27.
2. Clatworthy AE, Pierson E, Hung DT, (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3: 541-548.
3. Lynch SV, Wiener-Kronish JP, (2008) Novel strategies to combat bacterial virulence. Curr Opin Crit Care 14: 593-599.
4. Svensson A, Larsson A, Emtenäs H, Hedenström M, Fex T, et al. (2001) Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2: 915-918.
5. Panchal RG, Hermone AR, Nguyen TL, Wong TY, Schwarzenbacher R, et al. (2004) Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 11: 67-72.
6. Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, et al. (2005) Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A 102: 7958-7963.
7. Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, et al. (2006) A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 103: 14566-14571.
8. Hudson DL, Layton AN, Field TR, Bowen AJ, Wolf-Watz H, et al. (2007) Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother 51: 2631-2635.
9. Lyon GJ, Wright JS, Muir TW, Novick RP, (2002) Key determinants of receptor activation in the agr autoinducing peptides of Staphylococcus aureus. Biochemistry 41: 10095-10104.
10. Thiagarajah JR, Verkman AS, (2005) New drug targets for cholera therapy. Trends Pharmacol Sci 26: 172-175.
11. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, et al. (2001) GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45: 2340-2347.
12. Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr, (2008) Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents Chemother 52: 2190-2195.
13. Schneemann A, Manchester M, (2009) Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol 4: 35-43.
14. Strockbine NA, Marques LR, Holmes RK, O'Brien AD, (1985) Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 50: 695-700.
15. Peterson JW, Hejtmancik KE, Markel DE, Craig JP, Kurosky A, (1979) Antigenic specificity of neutralizing antibody to cholera toxin. Infect Immun 24: 774-779.
16. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, et al. (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99: 11346-11350.
17. Lowy, Molrine DC, Leav BA, Blair BM, Baxter R, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197-205.
18. Kink JA, Williams JA, (1998) Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66: 2018-2025.
19. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, et al. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74: 6339-6347.
20. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, et al. (2011) Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286: 8961-8976.
21. Hussack G, Tanha J, (2010) Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspecties. Toxins 2: 998-1018.
22. Bebbington C, Yarranton G, (2008) Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19: 613-619.
23. Jank T, Aktories K, (2008) Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16: 222-229.
24. Tjellström B, Stenhammar L, Eriksson S, Magnusson KE, (1993) Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 341: 701-702.
25. Davidson GP, Whyte PB, Daniels E, Franklin K, Nunan H, et al. (1989) Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 2: 709-712.
26. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, et al. (1992) Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 47: 276-283.
27. Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, et al. (1988) Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 318: 1240-1243.
28. Yokoyama H, Peralta RC, Diaz R, Sendo S, Ikemori Y, et al. (1992) Passive protective effect of chicken egg yolk immunoglobulins against experimental enterotoxigenic Escherichia coli infection in neonatal piglets. Infect Immun 60: 998-1007.
29. Reilly RM, Domingo R, Sandhu J, (1997) Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 32: 313-323.
30. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
31. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S, (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414: 521-526.
32. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198: 157-174.
33. Harmsen MM, van Solt CB, Hoogendoorn A, van Zijderveld FG, Niewold TA, et al. (2005) Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. Vet Microbiol 111: 89-98.
34. Krüger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, et al. (2006) Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol 72: 732-737.
35. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, et al. (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24: 4130-4137.
36. Young NM, MacKenzie CR, Narang SA, Oomen RP, Baenziger JE, (1995) Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett 377: 135-139.
37. Hagihara Y, Mine S, Uegaki K, (2007) Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J Biol Chem 282: 36489-36495.
38. Saerens D, Conrath K, Govaert J, Muyldermans S, (2008) Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol 377: 478-488.
39. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, et al. (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284: 14203-14210.
40. Wörn A, Plückthun A, (1998) Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37: 13120-13127.
41. Sieber V, Plückthun A, Schmid FX, (1998) Selecting proteins with improved stability by a phage-based method. Nat Biotechnol 16: 955-960.
42. Jung S, Honegger A, Plückthun A, (1999) Selection for improved protein stability by phage display. J Mol Biol 294: 163-180.
43. Jermutus L, Honegger A, Schwesinger F, Hanes J, Plückthun A, (2001) Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci U S A 98: 75-80.
44. Matsuura T, Plückthun A, (2003) Selection based on the folding properties of proteins with ribosome display. FEBS Lett 539: 24-28.
45. Famm K, Hansen L, Christ D, Winter G, (2008) Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 376: 926-931.
46. Famm K, Winter G, (2006) Engineering aggregation-resistant proteins by directed evolution. Protein Eng Des Sel 19: 479-481.
47. Christ D, Famm K, Winter G, (2007) Repertoires of aggregation-resistant human antibody domains. Protein Eng Des Sel 20: 413-416.
48. Jespers L, Schon O, Famm K, Winter G, (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22: 1161-1165.
49. Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG, (2006) Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol 72: 544-551.
50. Chan PH, Pardon E, Menzer L, De Genst E, Kumita JR, et al. (2008) Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry 47: 11041-11054.
51. Arbabi-Ghahroudi M, MacKenzie R, Tanha J, (2009) Selection of non-aggregating VH binders from synthetic VH phage-display libraries. Methods Mol Biol 525: 187-216 xiii.
52. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR, (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.
53. Arbabi-Ghahroudi M, Mackenzie R, Tanha J, (2010) Site-directed mutagenesis for improving biophysical properties of VH domains. Methods Mol Biol 634: 309-330.
54. Greenfield NJ, (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1: 2876-2890.
55. Greenfield NJ, (2006) Analysis of the kinetics of folding of proteins and peptides using circular dichroism. Nat Protoc 1: 2891-2899.
56. Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, et al. (2009) Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 4: 1-13.
57. Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K, et al. (2000) Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 39: 1217-1222.
58. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, et al. (2004) Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 279: 51965-51972.
59. Wu SL, Jiang H, Lu Q, Dai S, Hancock WS, et al. (2009) Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Anal Chem 81: 112-122.
60. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, et al. (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11: 500-515.
61. To R, Hirama T, Arbabi-Ghahroudi M, MacKenzie R, Wang P, et al. (2005) Isolation of monomeric human VHs by a phage selection. J Biol Chem 280: 41395-41403.
62. Wang W, Nema S, Teagarden D, (2010) Protein aggregation-pathways and influencing factors. Int J Pharm 390: 89-99.
63. Hubbard SJ, Beynon RJ, Thornton JM, (1998) Assessment of conformational parameters as predictors of limited proteolytic sites in native protein structures. Protein Eng 11: 349-359.
64. Frenken LG, Egmond MR, Batenburg AM, Verrips CT, (1993) Pseudomonas glumae lipase: increased proteolytic stability by protein engineering. Protein Eng 6: 637-642.
65. Balan KK, Jones AT, Roberts NB, Pearson JP, Critchley M, et al. (1996) The effects of Helicobacter pylori colonization on gastric function and the incidence of portal hypertensive gastropathy in patients with cirrhosis of the liver. Am J Gastroenterol 91: 1400-1406.
66. Schmidt P, Wiedemann V, Kühlmann R, Wanke R, Linckh E, et al. (1989) Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases. II. In vitro studies on gastric and enteric digestion of egg yolk antibodies specific against pathogenic Escherichia coli strains. Zentralbl Veterinarmed B 36: 619-628.
67. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A, (2010) Needle-free influenza vaccination. Lancet Infect Dis 10: 699-711.
68. Werle M, Makhlof A, Takeuchi H, (2009) Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul 3: 94-104.
69. Li S, Zheng W, Kuolee R, Hirama T, Henry M, et al. (2009) Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Mol Immunol 46: 1718-1726.
70. Kim DY, Ding W, Tanha J, (2011) Solubility and stability engineering of human VH domains. Methods Mol Biol (In press).